Zelira Therapeutics Ltd
ASX:ZLD

Watchlist Manager
Zelira Therapeutics Ltd Logo
Zelira Therapeutics Ltd
ASX:ZLD
Watchlist
Price: 0.35 AUD -5.41% Market Closed
Market Cap: 4.2m AUD

Relative Value

ZLD doesn't have a meaningful market cap.

The Relative Value of one ZLD stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.35 AUD, Zelira Therapeutics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZLD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
6
vs Industry
23
Median 3Y
39.4
Median 5Y
26.2
Industry
2.6
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.3
Industry
21.4
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.5
Industry
16.4
vs History
vs Industry
Median 3Y
-3
Median 5Y
-3.4
Industry
22.8
vs History
vs Industry
78
Median 3Y
-0.8
Median 5Y
0.3
Industry
2.2
vs History
6
vs Industry
11
Median 3Y
94.3
Median 5Y
23
Industry
2.9
vs History
vs Industry
17
Median 3Y
8.8
Median 5Y
21.8
Industry
5.5
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.5
Industry
13
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.5
Industry
16.5
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.1
Industry
15.6
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.1
Industry
18.7
vs History
vs Industry
81
Median 3Y
-2.8
Median 5Y
0.3
Industry
1.9

Multiples Across Competitors

ZLD Competitors Multiples
Zelira Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Zelira Therapeutics Ltd
ASX:ZLD
4.2m AUD 5 948.6 -1.1 -2.3 -2.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.7 37.4 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
270.6B CHF 4.4 28.7 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
219.5B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
217.9B CHF 4.9 18.9 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.1 11.2 13
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.8B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
AU
Zelira Therapeutics Ltd
ASX:ZLD
Average P/E: 25
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.1
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Zelira Therapeutics Ltd
ASX:ZLD
Average EV/EBITDA: 440
Negative Multiple: -2.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Zelira Therapeutics Ltd
ASX:ZLD
Average EV/EBIT: 1 883.7
Negative Multiple: -2.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5